Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca commences phase III trials for depression drug

AstraZeneca commences phase III trials for depression drug

25th June 2010

AstraZeneca has commenced a phase III clinical trial programme to support the regulatory approval application of a new adjunct treatment for major depressive disorder.

The pharmaceutical company has enrolled the first patient in the Renaissance programme, which will be used to evaluate the efficacy and tolerability profile of TC-5124, a nicotinic channel blocker, when compared to placebo.

TC-5124 is designed to aid patients who have previously demonstrated an inadequate response to first-line therapy using a selective serotonin reuptake inhibitor or a serotonin/norephinephrine reuptake inhibitor.

AstraZeneca hopes that positive results from the programme will support a planned new drug application with the US Food and Drug Administration in the second half of 2012.

This is set to be followed by a European application in 2014.

Earlier this week, the company published new trial results for its non-small cell lung cancer treatment Iressa, which illustrated the advantages it offers compared to chemotherapy.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.